EMA Application withdrawn: Folcepri (Etarfolatide) — Endocyte Europe, B.V.

View source ↗

Summary

EMA withdrawal of the Folcepri (Etarfolatide) application by Endocyte Europe, B.V. for indications in ovarian neoplasms and radionuclide imaging.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Folcepri (Etarfolatide)

Snippet

Status: Application withdrawn. Therapeutic area: Ovarian Neoplasms;Radionuclide Imaging. MAH: Endocyte Europe, B.V.. Decision date: 21/03/2014. Orphan medicine